Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Growing
The company is in a growing phase, with the latest annual income totaling USD 44.55M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 44.55M.
Fairly Valued
The company’s latest PE is -6.86, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 74.94M shares, decreasing 9.08% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 912.50K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.01.